Literature DB >> 29794202

Clinical Pharmacology of Corticosteroids.

Dennis M Williams1.   

Abstract

Corticosteroids have numerous applications in treating inflammation and diseases of immune function based on their significant anti-inflammatory and immunosuppressive effects. Corticosteroids modulate immune function through various effects in the nucleus of numerous cells. When used in pharmacologic doses to suppress allergic responses or inflammation, these agents can cause numerous adverse effects associated with an excess of glucocorticoid activity. Prolonged use (>2 wk) results in suppression of the hypothalamic-pituitary-adrenal axis, which requires tapering of doses. Dosing strategies for systemic corticosteroids are designed to minimize the risk for hypothalamic-pituitary-adrenal axis suppression. Topical administration of corticosteroids, including oral inhalation, is often used to avoid the significant adverse effects associated with chronic use. Inhaled corticosteroids are potent synthetic agents that exert their actions locally in the airways but can cause systemic effects based on several factors that influence systemic bioavailability. Inhaled corticosteroids are the cornerstone of asthma therapy and important options for COPD in patients who experience frequent exacerbations. By the nasal route, they are the most effective therapy for treating moderate-to-severe allergic rhinitis.
Copyright © 2018 by Daedalus Enterprises.

Entities:  

Keywords:  COPD; asthma corticosteroids; lung disease

Mesh:

Substances:

Year:  2018        PMID: 29794202     DOI: 10.4187/respcare.06314

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  46 in total

Review 1.  The interaction of steroids with phospholipid bilayers and membranes.

Authors:  Jackson Crowley; Minduli Withana; Evelyne Deplazes
Journal:  Biophys Rev       Date:  2021-12-02

Review 2.  Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature.

Authors:  Lindsay K Harris; Andrew J Crannage
Journal:  J Pharm Technol       Date:  2021-02-22

Review 3.  The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19.

Authors:  Heloísa Antoniella Braz-de-Melo; Sara Socorro Faria; Gabriel Pasquarelli-do-Nascimento; Igor de Oliveira Santos; Gary P Kobinger; Kelly Grace Magalhães
Journal:  Front Med (Lausanne)       Date:  2021-04-23

4.  Corticosteroid therapy for 2019-nCoV-infected patients: A case series of eight mechanically ventilated patients.

Authors:  Mabrouk Al-Rasheedi; Yasir Alhazmi; Nouf Almaqwashi; Alreshidi Mateq Ali; Abdulaziz Kardam; Mohammod Sharaf; Khawaja Husnain Haider
Journal:  Clin Case Rep       Date:  2021-03-26

Review 5.  Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia.

Authors:  Zeyar T Htun; Elizabeth V Schulz; Riddhi K Desai; Jaime L Marasch; Christopher C McPherson; Lucy D Mastrandrea; Alan H Jobe; Rita M Ryan
Journal:  J Perinatol       Date:  2021-05-19       Impact factor: 2.521

6.  Cyclophilin A Plays Potential Roles in a Rat Model of Asthma and Suppression of Immune Response.

Authors:  Cai-Tao Chen; Chun-Xiao Shan; Jun Ran; Lei-Miao Yin; Hai-Yan Li; Yu Wang; Yu-Dong Xu; Jing-Lei Guo; Yang-Lin Shi; Yan-Jiao Chen; Yong-Qing Yang
Journal:  J Asthma Allergy       Date:  2021-05-07

7.  Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice.

Authors:  Mikkel Bo Brent; Jesper Skovhus Thomsen; Annemarie Brüel
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

8.  Serum 8-isoprostane levels in patients with resistant oral lichen planus before and after treatment with lycopene: a randomized clinical trial.

Authors:  Aliaa Abdelmoniem Bedeir Eita; Azza Mohamed Zaki; Sabah Abdelhady Mahmoud
Journal:  BMC Oral Health       Date:  2021-07-15       Impact factor: 2.757

Review 9.  Could Exogenous Insulin Ameliorate the Metabolic Dysfunction Induced by Glucocorticoids and COVID-19?

Authors:  Martin Brunel Whyte; Prashanth R J Vas; Anne M Umpleby
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-18       Impact factor: 5.555

10.  Coadministration of a Clinically Relevant Dexamethasone Dosage With Ablative Radiation Therapy Reduces Peripheral Lymphocytes But Does Not Alter In Vivo Intratumoral Lymphocyte Phenotype or Inhibit Efficacy of Radiation Therapy in a Murine Colorectal Tumor Model.

Authors:  Nicholas G Battaglia; Taylor P Uccello; Angie Hughson; Jesse Garrett-Larsen; Johnathan J Caldon; Haoming Qiu; Scott A Gerber; Edith M Lord
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-04-30       Impact factor: 8.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.